Pages

Share This

Showing posts with label vaccine. Show all posts
Showing posts with label vaccine. Show all posts

Tuesday, April 19, 2022

Senior citizens with high-risk comorbidities eligible for second booster shot

Khairy: Currently, the Comirnaty mRNA vaccine (Pfizer-BioNTech) is the recommended vaccine for a second booster dose based on available scientific data. (Photo by Zahid Izzani Mohd Said/The Edge) 
Khairy: Currently, the Comirnaty mRNA vaccine (Pfizer-BioNTech) is the recommended vaccine for a second booster dose based on available scientific data. (Photo by Zahid Izzani Mohd Said/The Edge)

 KUALA LUMPUR (April 14): Senior citizens with high-risk comorbidities are eligible to receive a second Covid-19 booster shot four to six months after their first booster dose, Health Minister Khairy Jamaluddin said on Thursday.

Khairy also said that severely immunocompromised individuals aged 12 and above may receive their first booster jab within 28 days of receiving the second Covid-19 vaccine.

"It is not mandatory but optional, and it will be made through appointments," he told a press conference.

Khairy said those aged 60 and above who are healthy and not at risk for comorbidities should discuss with their doctor whether a second booster vaccination would be recommended for them.

Meanwhile, senior citizens who have received a booster vaccination and have tested positive for Covid-19 can receive a second booster vaccination three months after their full recovery, he said.

The minister said Pfizer-BioNTech Comirnaty's vaccine is the recommended vaccine for a second booster dose based on scientific data available.

On the booster shot for teenagers, Khairy said: "We leave it to the parents to talk to medical practitioners to make a decision. There is no coercion."

The minister said the implementation of this latest recommendation will not affect the full vaccination status of high-risk individuals who do not receive a second booster dose. The Health Ministry is currently updating clinical guidelines detailing implementation, he said.

Khairy said the ministry has also received requests from individuals who want to travel abroad to receive a second booster dose to meet the travel requirements.

"For example, there are some countries in continental Europe that do not recognise Sinovac and Sinopharm vaccines as first and booster doses," he said.

"Therefore, people who want to go abroad can receive a second booster dose at least one month apart after the first booster dose to meet the requirements of going abroad," he said.

As of March 31, a total of 701 individuals had received digital certificates of exemption from vaccination for medical reasons.

These individuals will also automatically receive a booster vaccination exemption.

"Individuals who are not eligible for a booster vaccination for medical reasons, especially the primary Sinovac or Sinopharm recipients or senior citizens who have not yet received a digital vaccination exemption certificate will need to submit a new application.

"They must obtain confirmation from a medical practitioner and then submit an application to the nearest district health department," said Khairy.

Adam Aziz & S Kanagaraju

  Source link.  

Seniors open to second booster dose

PETALING JAYA: Feeling boosted by the protection offered by the vaccine, many Covid-19-conscious senior citizens say they are receptive to taking a fourth dose.

Leong King Soon, 62, and his wife Barbara Teoh, 60, have hypertension and diabetes respectively and with their comorbidities, they are among the senior citizens now eligible to get a fourth shot of the Covid-19 vaccine.

Leong, who took his first booster in December, said he and his wife have so far not contracted Covid-19.

“I have been in close contact with Covid-19 individuals many times as I work as an industrial machine repairman and go to many factories for my job but so far so good.

“Besides taking the standard operating procedure seriously such as wearing a face mask and frequently washing hands, I really think that the three doses of the Covid-19 vaccine I took have kept me protected until now.

“So when the time comes for the fourth dose, I will definitely go get it with my wife,” said Leong.

He added that Teoh, too, had been in close contact unwittingly with Covid-19-positive friends and relatives but she has also been safe so far.

“She only took her first booster last month as she was ill over the past few months and needed her doctor’s clearance,” added Leong.

On Thursday, Health Minister Khairy Jamaluddin said senior citizens with comorbidities can get the fourth shot between four and six months after their first booster, while seniors without comorbidities can get a second booster provided they get approval from their doctor.

Seniors who have received their booster dose but have been infected with Covid-19 will be eligible for a fourth shot three months after they recover.

Leong had this to say: “Get the booster for your own protection and ignore all the negative stories that you hear. People don’t remember the positive stories but like to hang on to the negative ones.”

Trader Saifuddin Omar, 67, who has diabetes and hypertension, also believes that the Covid-19 vaccine he took has protected him from the virus.

“Recently, my daughter and her son, who live with me, got infected but they didn’t know until five days later. We all share the same bathroom and eat at the same table but my wife and I didn’t get infected.

“My daughter and grandson (aged eight) are fully vaccinated and only suffered mild symptoms,” he said.

Saifuddin recalled initially feeling scared last year about taking the vaccine after hearing stories about the side effects.

“But now I see that it does help, I feel encouraged to take the fourth dose of the vaccine and will do so soon,” said Saifuddin, adding that he and his wife had their first booster in January.

Retired teacher B. Parimala, 63, does not have any comorbidities and took her first booster last year.

While seniors without comorbidities can get a second booster with their doctor’s approval, Parimala said she would rather wait.

“I was a science teacher so I keep up to date with the latest news about the vaccine.

“I recently read that boosting too often and with the same type of vaccine could reduce one’s immunity, especially against new variants.

“So I’d rather wait than go for the second booster now,” she said.

Parimala, too, warned against adopting a lackadaisical attitude towards Covid-19.

“Long Covid is no joke. My former colleague has such bad scarring on her lungs that she gets winded just walking a short distance. We should all continue to keep ourselves protected,” she said. 

 Source link.   

Related News

Monday, February 22, 2021

Covid-19 vaccines are here. Here's what you need to know to begin vaccination Feb 24, 2021

 

A nurse simulating giving a vaccine jab to a volunteer during the exercise at the Serian community hall. Ñ ZULAZHAR SHEBLEE/The Star

 


PETALING JAYA: With the arrival of the first batch of Covid-19 vaccines in Malaysia, many are eager to know what happens next and when they can get their shots.

To date, the country has bought 66.7mil doses of vaccines from five Covid-19 vaccine producers, enough to vaccinate 109.65% of Malaysia's population.

The vaccination is voluntary and will be provided free of charge to everyone living in Malaysia, including non-citizens.

The vaccine will only be offered to people aged 18 years and above, though this will be re-evaluated if needed.

Here are other key details about Malaysia's National Covid-19 Immunisation Programme:

The Pfizer-BioNTech vaccine obtained conditional approval from the Drug Control Authority (DCA) and the National Pharmaceutical Regulatory Agency (NPRA) on Jan 8, 2021.

The remaining four Covid-19 vaccine candidates are still pending approval from the NPRA.

The vaccines from these five suppliers will be received in stages by Malaysia from February 2021, subject to NPRA approval.

Take the quiz below to know when you can expect to receive your vaccine:

Flourish logoA Flourish data visualization

You can register starting March 1, 2021 to receive the vaccine.

There will be five ways to register, namely through:

How old are you?

Choose 1 of the following

* The MySejahtera application

* A hotline that will be launched soon

* An outreach programme for rural and interior areas

* www.vaksincovid.gov.my

* Registration at public and private health facilities

Appointment details such as dates and vaccination centre will be provided via the MySejahtera application, phone calls or SMS.

Vaccination feature appears in MySejahtera app | The Star



Source link: https://www.thestar.com.my/news/nation/2021/02/21/interactive-covid-19-vaccines-are-here-here039s-what-you-need-to-know

Related:

Khairy: China-made vaccine to arrive on Feb 27 | The Star
https://www.thestar.com.my/news/nation/2021/02/20/khairy-china-made-vaccine-to-arrive-on-feb-27

Vaccination to begin Feb 24 | The Star
https://www.thestar.com.my/news/nation/2021/02/22/vaccination-to-begin-feb-24

Related posts:

Convincing the non-believers for vaccination
https://rightwayspro.blogspot.com/2021/02/convincing-non-believers-for-vaccination.html

Monday, June 8, 2020

China's Covid-19 vaccine will be available for all, could be ready for public use early next year

China will make its Covid-19 vaccine a global public good when it is ready for application after successful research and clinical trials, a senior Chinese official said.

Finding a cure: An engineer conducting tests on an experimental vaccine for Covid-19 at a laboratory in Beijing

.


Wang Zhigang, minister of science and technology, said at a press conference in Beijing yesterday that international cooperation should be strengthened in vaccine development, clinical trials and application.

Vaccine development should focus on ensuring safety, effectiveness and accessibility, he added.


To date, four inactivated vaccines and one adenovirus vaccine had been approved for clinical trials, said a white paper titled “Fighting Covid-19: China in Action”, which was released by the State Council Information Office yesterday.

While scientists in China and abroad had kept up with mutual developments, China led the world in the development of certain types of vaccines, the white paper said.

A great deal of international cooperation had been carried out so far in terms of vaccine development, according to Wang.

Highlighting the significant role that vaccines had played in human history, Wang said both Chinese scientists and those in other countries were trying to make contributions to building a global community of health for all.

He, however, noted that the development of vaccines is a rigorous and complex procedure, which faces many uncertainties and may take a long period of time.

Wang also said drug research and development had been a priority in the efforts of fighting the pandemic in China since the very start, with more than 160 research institutes and enterprises taking part in various programmes.

Meanwhile, Ma Xiaowei, minister of the National Health Commission, said at the press conference that China would strengthen the building of public health emergency response system as the Covid-19 pandemic had exposed flaws in the country’s medical and public health system.

The country would improve the investment mechanism on public health system so that it would be in a better situation to handle disease prevention and control, he said.

Different levels of disease prevention and control centres would have a clearer definition of their functions, with the Chinese Centre for Disease Control and Prevention making the final decision on scientific research, testing, guidance and pathogenic analysis on epidemic diseases, Ma added.

“Moreover, we will further improve the reporting and warning system of major public health incidents by building public opinion monitoring system, reporting system by medical workers and reporting system on scientific findings,” he said.

There would also be new policies in cultivating more talents in public health and improving their treatment, especially talents in pathogenic detection, epidemiological investigation, laboratory testing and analysis on epidemic situation, he added.

China could have Covid-19 vaccine ‘ready for public use early next year’


Three vaccines developed by Chinese companies and researchers are in their second or third phase of trials. - Reuters
  China may have a vaccine against the  deadly Covid-19 for emergency use by September and for the general public early next year, a top Chinese public health expert has said..

This is the first time a Chinese official has put an estimate on the timescale for development of a coronavirus vaccine, believed to be the key to containing the global pandemic. The US Food and Drug Administration believes a vaccine in the United States could be at least a year away, and the World Health Organisation (WHO) has said that it could take 12 to 18 months..

Gao Fu, head of the Chinese Centre for Disease Control and Prevention, on Thursday told China Global Television Network, the overseas arm of the state broadcaster, that vaccines currently at phase two or three of clinical trials could be available by the time of a potential second wave of outbreaks. Three Chinese vaccines have completed the first phase of trials.

“We are in the frontline for the vaccine development, and we may have a vaccine ready for emergency use by September,” Gao said. “These newly developed vaccines, which are still under phase two or phase three clinical trials, could be used for some special groups of people, for example health care workers.”.

https://youtu.be/WsUFEd1_bws br />
Gao added that “we may have a vaccine for the healthy population early next year”, but stressed that its feasibility would depend on “progress of our development”..

Unlike influenza – whose frequent mutations must be anticipated by vaccine makers preparing for seasonal outbreaks – Sars-Cov-2, the virus that causes the disease Covid-19, is believed not to mutate as often and is unlikely to become a “new norm” such as seasonal flu, according to virologist Shi Yi, of the Institute of Microbiology, Chinese Academy of Sciences..

“Some experts believe the epidemical new coronavirus will become a norm and spread like the influenza virus... but [we believe] such probability would be relatively low,” Shi told reporters at a regular briefing in Beijing on Thursday. “At present, there is no evidence that the new coronavirus has the same variability as influenza virus.”.

https://youtu.be/8oQM48rToSc

Shi also rejected the possibility of Covid-19 becoming a chronic illness, given that the virus multiplies mainly in patients’ respiratory tracts and no continuous virus carrying has been observed. He added that the same was true of the century’s two other known coronavirus-induced diseases, severe acute respiratory syndrome (Sars) and Middle East respiratory syndrome (Mers)..

As the coronavirus has swept the globe and infected more than 2.7 million people, causing nearly 200,000 deaths, scientists have raced to develop a vaccine to combat the pandemic. By Thursday, six candidates had entered into clinical trials and 77 others were in preclinical studies, according to the WHO..

https://youtu.be/vfL7DzdNl54

Newly added to the group being trialled was a viral vector vaccine developed by a team of researchers from the University of Oxford, which was injected into its first two volunteers on Thursday and was based on a technology used to develop a vaccine for Mers..

The team’s leader, Dr Sarah Gilbert, reportedly expressed hope that 1 million doses would be ready for use by September.

Trump adviser claims China may be keeping data to win virus vaccine race


US biotech start-up Moderna started the world’s first coronavirus clinical trial in March, on its mRNA vaccine. Another US company, Inovio Pharmaceuticals, kicked off its first human trial of a DNA vaccine last month..

Three vaccines developed by Chinese companies and researchers have passed their first phase of trials for safety and earlier this month started the second phase, involving hundreds to more than 1,000 volunteers testing their effectiveness and researchers assessing vaccination doses..

https://youtu.be/UEzZ6sZegso

The trio included the Adenovirus-vector vaccine, by Tianjin-based Cansino Biological I and Beijing Institute of Biotechnology, and two inactivated vaccines developed by the Wuhan Institute of Biological Products and Sinovac Research & Development in Beijing..

China has experienced an easing of the Covid-19 epidemic after nearly five months of the outbreak, which was first reported in the central city of Wuhan. It reported only four locally transmitted and two imported cases on Thursday, while the number of patients still under treatment has fallen to below 1,700..

Existing drugs ‘may prove effective on coronavirus before vaccine comes’

But vaccines under development will require an effective patient population for the third phase of trials, to allow their effectiveness to be tested in an environment where the virus is still prevalent..

Researchers must overcome difficulties such as “vaccine enhancement”, in which a disease is exacerbated in a vaccinated person infected with the actual virus..

Sign up now now and get a 10% discount (original price US$400) off the China AI Report 2020 by SCMP Research. Learn about the AI ambitions of Alibaba, Baidu & JD.com through our in-depth case studies, and explore new applications of AI across industries. The report also includes exclusive access to webinars to interact with C-level executives from leading China AI companies (via live Q&A sessions). Offer valid until 31 May 2020..

Source link

More from South China Morning Post:

 

Researchers hit new milestone | The Star


Researchers hit new milestone


China Focus: China to make COVID-19 vaccine global public ...

 

China's coronavirus vaccine facility ready to make millions of ...


Covid-19: China offers US$2bil aid and promises to share ...

 

China pledges to make its coronavirus vaccine a 'public good ...


For the latest news from the South China Morning Post download our mobile app. Copyright 2020.


Related Posts:
 

China leads in coronavirus vaccine clinicals to combat Covid-19